Date: 2011-08-16
Type of information: R&D agreement
Compound: fully human therapeutic antibodies
Company: 4-Antibody AG (Switzerland) Human Genome Sciences (USA)
Therapeutic area:
Type agreement: collaboration
R&D
Action mechanism:
Disease:
Details: 4-Antibody AG has signed a collaboration agreement with Human Genome Sciences (HGS) to discover and develop fully human therapeutic antibodies. The collaboration with HGS is focused on 4-Antibody’s proprietary high throughput in vitro Retrocyte Display® technology for rapid discovery of fully human antibodies against novel targets nominated by HGS.
The Retrocyte Display® technology (Retroviral B lymphocyte Display) is a potent and fast tool for high quality therapeutic antibody discovery and optimization using a rapid flow cytometry approach. Full-length immunoglobulin antibody libraries are expressed in mammalian B-lineage cells, the cell designed by nature for optimal antibody display, resulting in "better-behaved", fully human antibodies. This collaboration agreement, which initially involves two projects, is 4-Antibody’s second such alliance with a pharmaceutical partner, the first being with Boehringer Ingelheim which commenced in early 2010.
Financial terms: Financial terms of the deal were not disclosed.
Latest news:
